PO.CL01.23 · 临床研究
通过牛津纳米孔(Oxford Nanopore)自适应测序结合新开发的生物信息学流程探索循环肿瘤细胞的基因突变
Exploring gene mutations of circulating tumor cells by Oxford nanopore adaptive sequencing implemented with a newly developed bioinformatic pipeline
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
循环肿瘤细胞(CTCs)是监测治疗反应和早期检测癌症患者的一种重要且易于获取的生物学材料。在本研究中,我们旨在开发一种精准工作流程,将基于免疫磁珠和阴性选择的CTCs富集与纳米孔自适应测序技术相结合,以检测癌症相关基因组区域中的突变并理解CTCs的内在特性。我们在先前研究中开发的PowerMag系统被用于从血液样本中清除白细胞并富集CTCs,随后进行全基因组扩增。扩增后的DNA使用牛津纳米孔GridIon设备进行纳米孔自适应测序,并使用BED文件定义76个常见癌症基因突变靶标区域。我们还自主开发了一个生物信息学分析平台,用于高效提取高置信度读段。突变核苷酸存在的置信度通过基于所指示核苷酸质量评分的逻辑(logistic)计算来确定。该工作流程已使用人外周血白细胞作为DNA的生物学来源进行了验证。此外,将OECM-1口腔癌细胞掺入人外周血的初步分析也表明,CTCs富集后进行自适应测序并使用自主开发的分析工具,即使在跨越基因突变区域的读段数量很少的情况下,也适用于鉴定癌症相关基因突变。综上所述,这一联合平台代表了一种对罕见CTCs进行实时、经济高效基因组分析的新工具,在癌症患者临床管理中具有潜在应用价值。
查看英文原文 English abstract
Circulating tumor cells (CTCs) represent an important and easily accessible biological material for monitoring treatment response and early detection of patients with cancer. In this study, we aimed to develop a precision workflow combining immunomagnetic bead- and negative selection-based enrichment of CTCs with the Nanopore adaptive sequencing technology to detect mutations in cancer-relevant genomic regions and to understand the intrinsic properties of CTCs. PowerMag system which we developed in our previous studies was used to deplete leukocytes and enrich CTCs from blood sample followed by whole genome amplification. The amplified DNA was subject to Nanopore adaptive sequencing using the Oxford Nanopore GridIon device and the BED file to define 76 common cancer gene mutation target regions. A bioinformatic analytical platform was also developed in-house for efficient extraction of high-confidence reads. The confidence for the presence of mutated nucleotides was determined by implementing a logistic calculation based on the quality score of the indicated nucleotides. The workflow has been validated by using human peripheral blood leukocytes as the biological source of DNA. In addition, preliminary analysis of OECM-1 oral cancer cells spiked into human peripheral blood also reveals that CTCs enrichment followed by adaptive sequencing and the use of analytical tools developed in-house are applicable to identify cancer-associated gene mutation even with a few numbers of reads spanning the gene mutation regions. Taken together, the combined platform represents a new tool for real-time, cost-effective genomic profiling of rare CTCs, with potential applications in the clinical management of cancer patients.
利益披露 Disclosure
T. Lee, None..
J. Wang, None..
S. Hou, None..
J. Cheng, None..
C. Tseng, None.